New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact. DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators. Regulatory Spark is designed to help founder-led biotech companies, scientific founders, academic spinouts, and tech transfer teams understand their likely route to…

Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica. Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions. Barry Callebaut has moved to the site to bolster its long-term presence at Colworth Science Park, home to The Magnum Ice Cream Company (TMICC). The move reinforces Barry Callebaut’s commitment to the local innovation…

Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face. Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart. Despite their vital work for those with rare diseases, the value of patient…

Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s co-founder and former CEO, transitions to the role…

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets. Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit. By leveraging its specialist clinical and regulatory expertise in novel medicinal products including cell and gene therapy development, Boyds has successfully navigated uncertainty across its clients’ markets, which…

LONDON, UK; MADRID, Spain; and SHORT HILLS, NJ – September 16, 2026 – Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.The appointments expand Coulter Partners' capabilities across Europe and North America, including the…

Peptide drug discovery is the process of designing, synthesising, testing and optimising peptide molecules to investigate biological targets or develop therapeutic candidates. Depending on the programme, peptides can be used for target validation, screening, structure-activity relationship (SAR) studies, optimisation and therapeutic development. Peptides occupy a distinctive chemical and pharmacological space between small molecules and larger biologics, combining high-affinity target recognition with substantial scope for sequence-level optimisation. It provides a powerful route to…

Download the UK Life Sciences Innovation Signals Report The UK life sciences sector continues to attract investment, strengthen research capabilities and advance scientific innovation. The key question facing the market is no longer whether innovation is being created. It is whether innovation can be converted into commercial growth, healthcare adoption and measurable patient impact. https://www.frazierdeeter.co.uk/wp-content/uploads/2026/08/UK-Life-Scie… The UK Life Sciences Innovation Signals report examines the latest data across three critical areas shaping the sector’s future: - Capital…

PIA Commercial are pleased to confirm the launch of our new website As One Nucleus members we work closely with life science companies in the UK and overseas to establish the insurance protection they require, and meets those needs Please have a look at the website which details how we can help you, and feel free to contact us by telephone , email, or via the website Kind regards Mike Cherrington Client Partnership Manager PIA Commercial Telephone 0121 694 6897 [email protected] www.piacommercial.com

Cambridge, UK, 28 July 2026 - One Nucleus expands its portfolio of member benefits through o2h co-discovery bringing discounted exclusive access for eligible One Nucleus members to specialist in-vitro ADME and DMPK services designed to support early-stage drug discovery. The initiative has been developed in response to the challenges many emerging biotech companies face in today's funding environment, where access to high-quality preclinical data is increasingly important for understanding compound behaviour, progressing programmes, raising investment and making confident business…